This is a working overview of fatty diacid chain, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-01-09. Anything still debated is marked as such rather than presented as settled.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | 31 amino acid residues |
| Molecular formula | C187H291N45O59 | free peptide, no counter-ion |
| Approximate mass | 4114 Da | matches theoretical value |
| Receptor target | Glucagon-like peptide-1 receptor | Gs-coupled, cyclic AMP pathway |
| Circulation half-life | About one week in humans | extended by albumin association |
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
The gene CALCA is notable for producing three distinct hormones with different effects. In addition to CGRP1, an alternative splicing encodes a precursor protein that is cleaved into calcitonin and katacalcin, which both function to reduce blood calcium levels. In addition to CGRP1, there is a second calcitonin gene-related peptide called CGRP2. This peptide is encoded by a separate gene, CALCB, but shares 90%+ homology (differing by 3 amino acids in humans). CGRP1 is traditionally considered the primary CGRP in the central and peripheral nervous system, while CGRP2 is mainly in the enteric nervous system.
To address these challenges, the Pittsburgh Model of Function deconstructs 'function' into five meanings to describe the different properties that are acquired by a locus undergoing de novo gene birth: Expression, Capacities, Interactions, Physiological Implications, and Evolutionary Implications. It is generally accepted that a genuine de novo gene is expressed in at least some context, allowing selection to operate, and many studies use evidence of expression as an inclusion criterion in defining de novo genes. The expression of sequences at the mRNA level may be confirmed individually through techniques such as quantitative PCR, or globally through RNA sequencing (RNA-seq). Similarly, expression at the protein level can be determined with high confidence for individual proteins using techniques such as mass spectrometry or western blotting, while ribosome profiling (Ribo-seq) provides a global survey of translation in a given sample. Ideally, to confirm a gene arose de novo, a lack of expression of the syntenic region of outgroup species would also be demonstrated. Genetic approaches to detect a specific phenotype or change in fitness upon disruption of a particular sequence, are useful to infer function. Other experimental approaches, including screens for protein-protein and/or genetic interactions, may also be employed to confirm a biological effect for a particular de novo ORF. Evolutionary approaches may be employed to infer the existence of a molecular function from computationally derived signatures of selection.
Submuscular pocket: The plastic surgeon emplaces the prosthetic breast beneath the pectoralis major muscle without cutting the inferior origin of that muscle. The total coverage of the prosthetic breast can be achieved by releasing the lateral muscles of the chest wall (either the serratus muscle or the pectoralis minor muscle) and then attach those lateral muscles to the pectoralis major muscle to augment the breast.
== Further reading == Glickman, N; Mitchell, HH (Jul 10, 1948). "The total specific dynamic action of high-protein and high-carbohydrate diets on human subjects" (PDF). The Journal of Nutrition. 36 (1): 41–57. doi:10.1093/jn/36.1.41. PMID 18868796.
Since October 1, 2007, it has been illegal for retailers to sell tobacco in all forms to people under the age of 18 in three of the UK's four constituent countries (England, Wales, Northern Ireland, and Scotland), increased from 16. It is also illegal to sell lighters, rolling papers, and all other tobacco-associated items to people under 18. It is not illegal for people under 18 to buy or smoke tobacco, it is only illegal for a retailer to sell a tobacco-associated item to them. The age increase from 16 to 18 came into force in Northern Ireland on September 1, 2008. In the Republic of Ireland, bans on the sale of smaller 10-packs and confectionery that resembles tobacco products (candy cigarettes) came into force on May 31, 2007, in a bid to cut underaged smoking. In October 2023, Prime Minister Rishi Sunak proposed a ban on sales of cigarettes to anyone born after 2008. Most countries in the world have a legal vending age of 18. In North Macedonia, Italy, Malta, Austria, Luxembourg, and Belgium, the age for legal vending is 16. Since January 1, 2007, all cigarette machines in public places in Germany must attempt to verify a customer's age by requiring the insertion of a debit card. Turkey, which has one of the highest percentages of smokers by population, has a legal age of 18. Japan is one of the highest tobacco-consuming nations, and requires purchasers to be 20 years of age. Since July 2008, Japan has enforced this age limit at cigarette vending machines through use of the Taspo smart card.
Sources: en.wikipedia.org
The USDA removed the table showing the Oxygen Radical Absorbance Capacity (ORAC) of Selected Foods Release 2 (2010) table due to the lack of evidence that the antioxidant level present in a food translated into a related antioxidant effect in the body.
(Sophy) Mr Crickson – Also known as Creaky to the foster boys: Fast Forward, Waddles, Swap-Out and Demon. He runs a farm and takes in foster boys to do manual labor such as tobacco cutting, barn repair and tending cattle. He treats the boys just well enough for the Department of Social Services (DSS) to allow him to continue to conduct foster care. (Mr. Creakle) Mr and Mrs McCobb – Parents of the foster home where Demon stays after Creaky's. Demon sleeps in the laundry room, which used to be where the dog was kept, and is expected to help pay his way by helping Mr McCobb stuff envelopes; Mr McCobb eventually finds Demon a job at Golly's Market where he sorts trash for cans, bottles and other things of value. The McCobb family is perpetually out of money and takes Demon in only for the money from DSS. (Wilkins Micawber and Emma Micawber) Betsy Woodall – Paternal grandmother who shows up on the day of Demon's birth, wanting to take him with her. After escaping the foster system, Demon seeks her out. She finds a home for Demon with Coach Winfield and his daughter Angus. (Betsey Trotwood) Brother Dick – Betsy’s physically disabled brother. He writes Shakespeare quotes on a huge kite. Demon eventually takes him out in his wheelchair to fly it. (Mr. Dick) Coach Winfield – Demon lives with him while in high school where Winfield is the celebrated football coach of the Generals. (Mr Wickfield) Angus – Coach Winfield's daughter; she and Demon have a relationship that Demon eventually recognizes as something that can last. (Agnes Wickfield) Ryan Pyles – Also known as U-Haul.
In signal processing, apodization (from Greek "removing the foot") is the modification of the shape of a mathematical function. The function may represent an electrical signal, an optical transmission, or a mechanical structure. In optics, it is primarily used to remove Airy disks caused by diffraction around an intensity peak, improving the focus.
== Transportation == UPS operates over 119,000 delivery vehicles worldwide, ranging from bicycles to tractor-trailer trucks. In a long-running company policy to avoid advertisement or endorsement of a vehicle manufacturer, all external manufacturer emblems and badging are removed when a vehicle enters service (whenever possible). The typical lifespan of a UPS ground vehicle is 20–25 years (or more), lasting until the structural integrity is compromised. The company does not re-sell any of its ground vehicles. As such, retired vehicles are almost always stripped of reusable parts before being sent to be crushed/broken up. Prior to scrapping, UPS trucks and trailers have all company branding painted over and are assigned an ADA (Automotive Destruction Authorization) number and must be crushed under the supervision of UPS Automotive personnel, which records the vehicle's destruction. The only exception to this policy are vehicles taken off the road for internal company use; package cars (repainted white) are used for various purposes (typically at large hubs); older semi tractors sometimes see use as terminal tractors.
The great danger of our situation consists in the fact that on the one hand, this is a war whose direction and decision are in the hands of the great powers engaged in it for life or death, and at the same time, we do not have a repertoire of tangible objectives to mark and govern our path... no pending territorial dispute... an invasion... we do not even have a common border with enemy countries.... We run the risk of entering into a rather ideological war of solidarity with the United States of America.... Under these conditions we are seriously exposed to a deadly annulment of our national personality. Nonetheless, labour leader and head of the Mexican left Vicente Lombardo Toledano supported the allied cause in the tribunes and advised the president not to take refuge in prudence because the time had come for the country to honor its traditions. The idea of national unity prevailed, and 1942 was declared the "Year of Effort", with the multiplication in all the media of allusive messages always accompanied by a Mexican flag such as:
Sources: en.wikipedia.org
It is a synthetic peptide of 31 amino acids, built to resemble the natural incretin hormone GLP-1. Because of its size and composition it is handled analytically like other therapeutic peptides, using chromatographic and mass spectrometric methods rather than the techniques typical of small organic drugs.
The substitution at position 8 removes the site recognised by dipeptidyl peptidase-4, the enzyme that destroys the native hormone within minutes. The linked lipophilic chain then binds circulating albumin, which further limits access by degradative enzymes and reduces renal loss. Together these features lengthen the effective circulation time considerably.
It acts at the glucagon-like peptide-1 receptor, a G protein-coupled receptor that signals mainly through cyclic AMP. Activation is glucose dependent, meaning insulin release is stimulated more strongly when blood glucose is already elevated. Other tissues carrying the same receptor respond as well, which explains effects beyond glucose control.
Native GLP-1 is degraded within minutes by circulating enzymes. The synthetic version carries substitutions at positions that block enzymatic cleavage, plus a fatty acid side chain that promotes albumin binding. These two changes together extend circulation time from minutes to roughly a week.